Skip to main content
Premium Trial:

Request an Annual Quote

Scipher Medicine Raises Series B Financing Total to $25M

NEW YORK – Scipher Medicine said on Wednesday that it has completed a second close in its previously announced Series B financing round, raising its total to $25 million with a new investment from Optum Ventures.

Based in Waltham, Massachusetts, Scipher is developing molecular tests to aid in therapeutic decision-making in the autoimmune disease space, using a proprietary approach for discovering RNA signatures. The first of these assays is PrismRA, a test to predict response to anti-tumor necrosis (anti-TNF) therapies in rheumatoid arthritis patients.

According to the company, Optum Ventures' investment, along with other Series B investments, will help accelerate its work on PrismRA and further its expansion into other difficult-to-treat and complex disease areas.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.